Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options

NEW YORK - (NewMediaWire) - July 08, 2021 - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ:ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant and/or traceable to the Company’s initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or between September 18, 2020 and June 17, 2021 (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ATHA.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.

The lawsuits allege that defendants issued materially false and misleading information and failed to disclose: (1) that CEO Dr. Leen Kawas had published research papers containing improperly altered images while she was a graduate student; (2) that this purported research was foundational to Athira’s efforts to develop treatments for Alzheimer’s because it laid the biological groundwork that Athira was using in its approach to treating Alzheimer’s; (3) that, as a result, Athira’s intellectual property and product development for the treatment of Alzheimer’s were based on invalid research; and (4) that, as a result of the foregoing, Defendants’ statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

On June 18, 2021, Athira shares plummeted 39% to $11.15, well below the $17.00 IPO price, after the Company disclosed that its Board decided to place Chief Executive Kawas on leave pending a review of actions stemming from research Dr. Kawas conducted while at Washington State University.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Athira’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.